mTOR activation in medullary thyroid carcinoma with RAS mutation
Authors:
- 1 November 2014
- journal article
- research article
- Published by Oxford University Press (OUP) in European Journal of Endocrinology
- Vol. 171 (5) , 633-640
Abstract
Objective: Rearranged during transfection (RET) mutations are well-known genetic events in sporadic and familial medullary thyroid carcinoma (FMTC). The presence ofRASmutations in sporadic cases, challenging theRETparadigm in these tumors, has been recently reported. We intend to evaluate mTOR pathway activation inRET- andRAS-mutated MTC.Materials and methods: In this study, we analysed the presence ofRET, H-RAS, andK-RASmutations in a series of 87 MTCs (82 apparently sporadic and five FMTCs; five apparently sporadic MTCs were eventually found to be familial). We also evaluated mTOR activation – using the expression of its downstream effector phospho-S6 ribosomal protein (p-S6) and the expression of the mTOR inhibitor, phosphatase and tensin homologue deleted on chromosome 10 (PTEN) – by immunohistochemistry.Results: Our results revealed thatRETmutations were present in 52.9% of the cases (46/87) andRASmutations in 12.6% (11/87) of the whole series of MTCs and 14.3% of the 77 sporadic MTCs. The presence ofRETandRASmutations was mutually exclusive.RASmutations were significantly associated with higher intensity of p-S6 expression (P=0.007), suggesting that the mTOR pathway is activated in such MTCs. We observed also an increased expression of p-S6 in invasive tumors (P=0.042) and in MTCs with lymph node metastases (P=0.046). CytoplasmicPTENexpression was detected in 58.8% of the cases; cases WT forRASshowed a significantly lower expression ofPTEN(P=0.045).Conclusions: We confirmed the presence ofRASmutation in 14.3% of sporadic MTCs and report, for the first time, an association between such mutations and the activation of the mTOR pathway. The evaluation of the mTOR activation by pS6 expression may serve as an indicator of invasive MTC.Keywords
This publication has 22 references indexed in Scilit:
- AZD1480 Blocks Growth and Tumorigenesis of RET- Activated Thyroid Cancer Cell LinesPLOS ONE, 2012
- SomaticRASMutations Occur in a Large Proportion of SporadicRET-Negative Medullary Thyroid Carcinomas and Extend to a Previously Unidentified ExonThe Journal of Clinical Endocrinology & Metabolism, 2012
- Activation of the mTOR Pathway in Primary Medullary Thyroid Carcinoma and Lymph Node MetastasesClinical Cancer Research, 2012
- Recent advances in the molecular pathogenesis and targeted therapies of medullary thyroid carcinomaCurrent Opinion in Oncology, 2012
- Phase II study of everolimus with biomarker exploration in patients with advanced gastric cancer refractory to chemotherapy including fluoropyrimidine and platinumBritish Journal of Cancer, 2012
- Phosphatidylinositol-3-Kinase as a Therapeutic Target in MelanomaClinical Cancer Research, 2009
- The phosphatidylinositol 3-kinase/akt signaling pathway in medullary thyroid cancerSurgery, 2008
- Tenets of PTEN Tumor SuppressionCell, 2008
- New therapeutic approaches to treat medullary thyroid carcinomaNature Clinical Practice Endocrinology & Metabolism, 2008
- Upstream and downstream of mTORGenes & Development, 2004